Business

Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic

Data could support future efforts to make real-time CGM a standard tool for glycemic assessment in the hospital setting Real-world evidence will be gathered

articleDexcom, Inc.September 16, 20205/company/dexcom-inc/news/dexcom-announces-first-ever-registry-dedicated-to-tracking-outcomes-of-in-hospital-real-time-cgm-use-in-response-to-the-covid-19-pandemic
Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic

About this update from Dexcom, Inc.

[{"type":"text","content":"\n\nData could support future efforts to make real-time CGM a standard tool for glycemic assessment in the hospital setting\n\n\nReal-world evidence will be gathered from healthcare providers and hospital institutions using real-time CGM with hospitalized patients\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nDexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today the first ever registry dedicated to tracking the outcomes of patients and healthcare professionals using CGM in hospitals in response to the COVID-19 pandemic.\n\nThe current standard-of-care for glucose monitoring in the hospital is a fingerstick blood glucose test, which requires healthcare providers to draw blood from a patient to obtain a glucose reading. Due to the need to preserve personal protective equipment, reduce potential hospital staff exposure to COVID-19 and lessen the overall burden on nursing care, the Dexcom G6 CGM system has been made available to remotely monitor the glucose levels of all hospitalized patients during the COVID-19 pandemic. The decision was made in April based on feedback received from the U.S. Food and Drug Administration (FDA).\n\n“In our previous use of the Dexcom G6 system in our hospitals as part of exploratory studies over the last three years, we have found that the device improves glucose control without any increased risk in hypoglycemia,” said Athena Philis-Tsimikas, M.D., endocrinologist and corporate vice president for the Scripps Whittier Diabetes Institute in San Diego. “More recently, we have begun using the system on some ICU and COVID-19 hospital floors where minimizing contact is important for both our patients and staff members. A registry to examine experiences across many hospitals would be hugely beneficial.”\n\nAbout the CGM registry\n\nThe registry will be accessible to healthcare providers using rtCGM in an inpatient or critical care setting. Providers will be able to upload information regarding the in-hospital care of each CGM patient, such as admissions, discharges, medications, status changes, diabetes history, comorbidities and more. The data collected will be deidentified and will not include any protected health information.\n\nThe data collected through the registry will eventually be cross-referenced with patient CGM data and evaluate...

More updates from Dexcom, Inc.